US2015157640A1PendingUtilityA1

Novel compounds

Assignee: GLAXO GROUP LTDPriority: Jun 23, 2004Filed: Feb 16, 2015Published: Jun 11, 2015
Est. expiryJun 23, 2024(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/12A61P 3/04A61P 9/04A61P 25/20A61P 27/02A61P 25/00A61P 15/12A61P 15/06A61P 15/08A61P 1/14A61P 13/12A61P 15/10A61P 15/00A61P 13/08A61P 1/16A61K 31/5377C07D 401/06A61K 31/496C07D 413/14C07D 413/06
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds of formula (I) wherein R 1 is 2-indanyl, R 2 is 1-methylpropyl, R 3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R 4 represents methyl and R 5 represents hydrogen or methyl or, R 4 and R 5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.

Claims

exact text as granted — not AI-modified
1 . A tablet for oral administration, wherein said tablet comprises 10-1000 mg of (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione or a pharmaceutically acceptable salt thereof. 
     
     
         2 . A tablet for oral administration, wherein said tablet comprises 10-1000 mg of (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione benzenesulfonate.

Join the waitlist — get patent alerts

Track US2015157640A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.